Shilpa Biologicals and SteinCares ink strategic pact to bring biosimilars to Latin America
New partnership combines Shilpa Biologicals’ development and manufacturing capabilities with SteinCares’ regional commercialization platform
New partnership combines Shilpa Biologicals’ development and manufacturing capabilities with SteinCares’ regional commercialization platform
The innovative eyedrop targets inflammation and pain following ocular surgery
Under the deal, Quiver will receive an undisclosed advance payment and research support
The new lineup features everything from the Color Fixation and Hair Therapy ranges to the Balanced Cleansing Shampoo and Nourishment & Protection Conditioner
Net sales reached CHF 1,327.8 million, up 2.6% year-on-year in Swiss francs, or 4.3% at constant exchange rates
Merck is currently conducting approximately 80 Phase 3 studies, and the company expects more than 20 new growth drivers over next several years, almost all with blockbuster potential
Expansion at the Oss (NL) site adds capacity and R&D capabilities, supporting the development and manufacturing of ADCs and other novel bioconjugates from First-in-Human to commercialization
Acquisition expands Axol’s portfolio of iPSC-derived retinal organoid and retinal pigment epithelium (RPE) models
The acquisition marks the company’s strategic entry into the fast-growing Hormone Replacement Therapy (HRT) segment and significantly strengthens its gynaecology portfolio in India
ANYRA is India’s first indigenously developed Aflibercept 2 mg biosimilar
Subscribe To Our Newsletter & Stay Updated